Serum antibody responses after intradermal vaccination against influenza
- PMID: 15525713
- DOI: 10.1056/NEJMoa043555
Serum antibody responses after intradermal vaccination against influenza
Abstract
Background: If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine.
Methods: In an open-label study, we randomly assigned 119 subjects to receive an intradermal injection of trivalent inactivated influenza vaccine, containing 6 mug of hemagglutinin for each antigen (40 percent of the usual dose), and 119 to receive an intramuscular injection of the standard dose of 15 mug of hemagglutinin for each antigen. The two groups were subdivided according to age (18 to 60 years and older than 60 years).
Results: Among subjects who were 18 to 60 years of age, serum antibody responses were vigorous and did not differ significantly between the intradermal and intramuscular groups, and all subjects had hemagglutination-inhibition (HAI) titers of at least 1:40. Although the subjects who were older than 60 years of age also had a vigorous antibody response, there was a trend toward a better response in the intramuscular route, but this finding was significant only for antigen to the H3N2 strain. Nevertheless, 100 percent of older subjects in the intramuscular group and 93 percent of such subjects in the intradermal group had an HAI antibody titer to the H3N2 strain of more than 1:40, and 100 percent in each group had a titer of this level for both the H1N1 and B strains. Local pain was significantly more common in the intramuscular group than in the intradermal group among subjects who were 18 to 60 years of age but not among subjects who were over 60 years old. Signs of local inflammation were significantly more common among subjects in the intradermal group than among those in the intramuscular group, in both age groups.
Conclusions: As compared with an intramuscular injection of full-dose influenza vaccine, an intradermal injection of a reduced dose resulted in similarly vigorous antibody responses among persons 18 to 60 years of age but not among those over the age of 60 years.
Copyright 2004 Massachusetts Medical Society.
Comment in
-
Intradermal influenza vaccination--can less be more?N Engl J Med. 2004 Nov 25;351(22):2330-2. doi: 10.1056/NEJMe048314. Epub 2004 Nov 3. N Engl J Med. 2004. PMID: 15525715 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. doi: 10.1056/NEJM200503103521019. N Engl J Med. 2005. PMID: 15758019 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. N Engl J Med. 2005. PMID: 15761999 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. N Engl J Med. 2005. PMID: 15762000 No abstract available.
-
Intradermal injection of reduced-dose influenza vaccine was highly immunogenic in persons </= 60 years of age but less so in persons > 60 years.ACP J Club. 2005 May-Jun;142(3):68-9. ACP J Club. 2005. PMID: 15862067 No abstract available.
Similar articles
-
Dose sparing with intradermal injection of influenza vaccine.N Engl J Med. 2004 Nov 25;351(22):2295-301. doi: 10.1056/NEJMoa043540. Epub 2004 Nov 3. N Engl J Med. 2004. PMID: 15525714 Clinical Trial.
-
Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. Pediatrics. 2006. PMID: 16950949 Clinical Trial.
-
Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?Pediatrics. 2006 Sep;118(3):e570-8. doi: 10.1542/peds.2006-0198. Pediatrics. 2006. PMID: 16950948 Clinical Trial.
-
Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.Expert Rev Vaccines. 2010 Oct;9(10):1127-33. doi: 10.1586/erv.10.117. Expert Rev Vaccines. 2010. PMID: 20923264 Review.
-
Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults.Expert Rev Vaccines. 2012 Jan;11(1):17-25. doi: 10.1586/erv.11.154. Expert Rev Vaccines. 2012. PMID: 22149703 Review.
Cited by
-
Developing Next-Generation Live Attenuated Vaccines for Porcine Epidemic Diarrhea Using Reverse Genetic Techniques.Vaccines (Basel). 2024 May 19;12(5):557. doi: 10.3390/vaccines12050557. Vaccines (Basel). 2024. PMID: 38793808 Free PMC article. Review.
-
Chrono-tailored drug delivery systems: recent advances and future directions.Drug Deliv Transl Res. 2024 Jul;14(7):1756-1775. doi: 10.1007/s13346-024-01539-4. Epub 2024 Feb 28. Drug Deliv Transl Res. 2024. PMID: 38416386 Free PMC article. Review.
-
Challenges in the Vaccination of the Elderly and Strategies for Improvement.Pathophysiology. 2023 Apr 22;30(2):155-173. doi: 10.3390/pathophysiology30020014. Pathophysiology. 2023. PMID: 37218912 Free PMC article. Review.
-
Microneedle-Mediated Immunization Promotes Lung CD8+ T-Cell Immunity.J Invest Dermatol. 2023 Oct;143(10):1983-1992.e3. doi: 10.1016/j.jid.2023.03.1672. Epub 2023 Apr 11. J Invest Dermatol. 2023. PMID: 37044258 Free PMC article.
-
Emerging adjuvants for intradermal vaccination.Int J Pharm. 2023 Feb 5;632:122559. doi: 10.1016/j.ijpharm.2022.122559. Epub 2022 Dec 28. Int J Pharm. 2023. PMID: 36586639 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials